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A cDNA for human 5-1ipoxygenase (5LO) was inserted into the vector pKC (constructed from pKK223-3 by replacing 
its replication origin with that of pUC 18) and expressed in Escherichia coli. The enzyme xpressed was purified to homo- 
geneity from the cellular soluble fraction. The purified enzyme showed both 5LO and leukotriene A 4 synthase activities, 
which were stimulated by Ca 2÷ and ATP. Its molecular mass (78 kDa) and NH2-terminal sequence were identical with 
those of 5LO purified from human leukocytes. The availability of the expression system will facilitate further studies 
on its regulation and the reaction mechanism of the enzyme. 
Lipoxygenase, 5-; Hydroperoxyicosatetraenoic acid,5-; Leukotriene A4; cDNA expression; (E. coli, Human) 
1. INTRODUCTION 
5-Lipoxygenase (5LO) catalyzes the conversion 
of arachidonic acid to 5-hydroperoxy-6,8,11,14- 
icosatetraenoic a id (5-HPETE) and the formation 
of leukotriene A4 (LTA4) from 5-HPETE [1-4]. 
LTA4 is further metabolized to LTB4, peptido- 
leukotrienes, LTC4, LTD4 and LTE4, all of which 
exhibit biological activities related to inflam- 
matory and allergic responses [5,6]. 5LO has been 
purified from sources such as human leukocytes 
[1,7], porcine leukocytes [2], rat basophilic 
leukemia cells [3,8], and mouse mastocytoma cells 
[4]. It requires Ca 2+ and ATP for maximal activity 
[1,4-7]. Human 5LO is also stimulated by uniden- 
tified cytosolic and membrane-bound proteins 
[7,9] and by sonicated phosphatidylcholine [10]. 
Recently, 5LO cDNAs derived from human 
placenta [11], dimethyl sulfoxide-differentiated 
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HL-60 cells [12], and rat basophilic leukemia cells 
[13] have been isolated. The human enzyme con- 
sists of 673 amino acid residues and its calculated 
molecular mass is about 78 kDa [11,12]. Here, we 
report the expression of human 5LO cDNA in 
Escherichia coli. 
2. MATERIALS AND METHODS 
2.1. Materials 
A human placental cDNA library in Agtll was purchased 
from Clontech (Palo Alto, CA), restriction enzymes and other 
DNA-modifying enzymes from Takara Shuzo (Kyoto), Nippon 
Gene (Toyama), and IBI (New Haven, CT), oligonucleotide- 
directed in vitro mutagenesis system from Amersham (Tokyo), 
pUC 18 and pUC 118 from Takara Shuzo (Kyoto) and pKK223-3 
from Pharmacia (Tokyo). 
2.2. Construction of expression vector 
Screening of the human placental cDNA library by plaque 
hybridization using a synthetic human 5LO DNA correspond- 
ing to 120 bases upstream from the terminator codon of 5LO 
cDNA resulted in the isolation of three positive clones. Of 
these, AplL5 (insert, 2.6 kbp) contained a 2073 bp open reading 
frame, in which two tandem 51 bp repeating units were found. 
AplL6 (2.2 kbp) and AplL7 (1.6 kbp) lacked one of the repeating 
units. As discussed in [11], the repeat in AplL5 was concluded 
to be due to a cloning artifact. A 2.3 kbp eDNA was cut out of 
APlL5 with BclI and EcoRI and ligated to pUCll8 that had 
been digested with EcoRI and BamHI. This construct, 
pH5LOUI, contained the tandem repeat between two XmaI 
sites (434 bp). ApL7 was digested with XmaI and the resulting 
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383 (434-51) bp fragment was ligated between the two XmaI 
sites of pH5LOU 1 to obtain pH5LOU2. This construct ontains 
the true human 5LO cDNA lacking the repeat. The 5'-non- 
coding segment between the EcoRI site and the initiator ATG 
codon of pH5LOU2 (see fig.l) was then deleted by oligo- 
nucleotide-directed in vitro mutagenesis to place 10 bases be- 
tween the Shine-Dalgarno sequence and the initiator ATG 
codon of 5LO cDNA. The 49-mer primer used was designed 
such that one half is complementary to 25 bases upstream of the 
EcoRl site of pH5LOU2 and the other half to 24 bases down- 
stream from the ATG codon. This primer was hybridized with 
single-stranded DNA of pH5LOU2 and, after second-strand 
synthesis, the double-stranded product was used to transform 
E. coli MV1184. A mutant clone was digested with EcoRI and 
HindlII, and the resulting EcoRI-HindlIl fragment containing 
5LO cDNA, from which part of the 5 '-noncoding region had 
been deleted, was inserted between the EcoRl and Hindlll sites 
of pKC to obtain the expression plasmid pH5LOKC, pKC was 
constructed from pKK223-3 by replacing the replication origin 
with that of pUC 18. The construction of the expression plasmid 
is outlined in fig.1. 
2.3. Purification of 5LO expressed in E. coli 
pH5LOKC was used to transform E. coli MV1184 as describ- 
ed by Hanahan [14]. The transformant was grown at 20°C for 
10 h in 1.8 1 of TYSG medium (1%0 Bactotryptone/0.5% yeast 
extract/2% NaC1/2%0 glycerol; pH 7.8). IPTG (final concen- 
tration, 0.2 mM) was then added and incubation continued for 
15 h. Cells were harvested by centrifugation (6000 × g, 10 min) 
and suspended in KP-1 buffer (50 mM potassium phos- 
phate/100 mM NaCI/2 mM EDTA/2 mM DTT/0.5 mM 
PMSF/60/~g/ml of soybean trypsin inhibitor; pH 7.1). After 
addition of lysozyme (10 mg/ml), the suspension was placed on 
ice for 30 min and then sonicated in a Biomic model 7250B 
ultrasonic processor at power level 4. A total sonication time of 
100 s was achieved using five 20-s periods at intervals of 30 s. 
The sonicate was centrifuged at 10000 × g for 10 min at 4°C. 
The resultant supernatant was fractionated with ammonium 
sulfate. The precipitate formed between 30 and 60% saturation 
was dissolved in 40ml TEG (50raM Tris-HC1/2mM 
EDTA/2 mM DTT/20% glycerol; pH 8.0) and dialyzed three 
times (3 h each) vs 100 vols TEG. The dialyzed sample was ap- 
plied to a Q-Sepharose (Pharmacia) column (26 x 300 mm) 
equilibrated with TEG, elution being conducted with a linear 
KCI gradient in TEG. Enzyme-containing fractions (eluates at 
0.25-0.35 M KCI) were combined, concentrated to 20 ml by 
ultrafiltration (PMI0, Amicon), and then dialyzed vs KP-2 buf- 
fer (10 mM potassium phosphate/2 mM DTT/20% glycerol; 
pH 7.6). The dialyzed material was applied to a Blue Sepharose 
CL-6B (Pharmacia) column (16 × 500 mm), equilibrated with 
KP-2 buffer, and eluted isocratically. The pooled enzyme frac- 
tions (elution volume 75-120 ml) were next subjected to 
chromatography on a hydroxyapatite (8010G, Mitsui Toatsu) 
column (8 x i00 mm) equilibrated with KP-2. When carrying 
out elution with a potassium phosphate gradient from 10 mM 
to 0.15 M, the enzyme was eluted at about 0.1 M. For further 
purification, the enzyme was diluted 4-fold with TEA (25 mM 
triethanolamine acetate/2 mM EDTA/2 mM DTT/30% 
glycerol; pH 7.8) and applied to a MonoQ HR 5/5 (Pharmacia) 
column (5 × 50 mm) equilibrated with TEA as in [7]. Upon elu- 
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Fig.1. Construction of plasmid pH5LOKC for expression of 
human 5LO cDNA in E. coil The clone, pH5LOU2, contains 
a 5'-noncoding region, nucleotide sequence corresponding to
674 amino acid residues between the initiator ATG codon and 
terminator TGA codon, and 3 '-noncoding region of human 
5LO cDNA. After deletion of the 5 '-noncoding region down- 
stream from the EcoRl site of pH5LOU2 by using an oligo- 
nucleotide-directed in vitro mutagenesis system, the modified 
5LO DNA was cut out with EcoRI and HindlII from 
pH5LOU2. The EcoRI-HindlII fragment was ligated into the 
vector pKC which was constructed from pKK223-3 by replacing 
the replication origin with that of pUC18. The resulting 
pH5LOKC was used for expression of the human 5LO gene in 
E. coli. 
tion with a sodium acetate gradient, the enzyme was obtained 
at 0.3-0.33 M and used for NH2-terminal sequence analysis. 
2.4. Enzyme assays 
The standard mixture for 5LO assay (total volume, 100/A) 
contained 0.1 M Tris-HC1 buffer (pH 7.5), 2 mM CaCI2, 2 mM 
ATP, 16/zg sonicated phosphatidylcholine, and enzyme. After 
preincubation (30°C, 2 rain), the reaction (30°C, 10 min) was 
initiated by addition of 8 nmol arachidonic acid and 20/zM 
nonenzymatically generated mixed HPETEs prepared as 
described [7] and terminated by addition of 0.3 ml cold 
( -20°C) methanol containing 0.2 nmol of 13-hydroxylinoleic 
acid as an internal standard and 1/~1 of 1 N acetic acid. Follow- 
ing centrifugation, the supernatant was analyzed by HPLC on 
a Capcellpak C18 column (4.6 × 150 mm, Shiseido) using 
methanol/water/acetic ac d(75:25:0.01, v/v) as solvent, with 
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detection of the absorbance being at 233 nm. 5LO activity was 
determined from the peak area ratio of 5-HPETE to the inter- 
hal standard. The assay mixture for LTA4 synthase activity was 
the same as above, the reaction being stopped by adding 2 ml 
cold ethanol containing 1nmol prostaglandin B~ (PGB0. The 
mixture was then processed via the Sep-Pak procedure [1], and 
analyzed by HPLC on a Nucleosil 3C18 (Chemco) column 
(4.6 × 100 mm) using methanol/acetonitrile/water/acetic 
acid/triethanolamine, pH 5.6 (0.5:0.8:1.2:0.025:0.028, v/v) as 
solvent. The flow rate was 1.0 ml/min, with detection of absor- 
barite at 270 nm. LTA4 synthase activity was determined from 
the peak area ratio of LTB4 isomers to PGB1. 
2.5. Other methods 
The oligonucleotides were synthesized in an Applied Bio- 
systems 381A DNA synthesizer. DNA sequencing was carried 
out via the dideoxy chain-termination method [15]. The 
NHz-terminal amino acid sequence was determined in an Ap- 
plied Biosystems 477A liquid-phase protein sequencer. SDS- 
PAGE was performed according to Laemmli [16]. Protein was 
evaluated as described by Bradford [17] with bovine serum 
albumin as a standard. 
3. RESULTS AND DISCUSSION 
The expression vector pKC was constructed 
from pKK223-3 by replacing its replication origin 
with that of pUC18, which displays a temperature- 
dependent copy number phenotype [18]. Then 
human 5LO cDNA was placed 10 bases 
downstream from the Shine-Dalgarno sequence of 
pKC to obtain the final expression plasmid 
pH5LOKC (fig. 1). 
When grown at 37°C, E. coli transformed with 
pH5LOKC expressed an SDS-PAGE-detectable 
protein of 78 kDa, which was recovered in the in- 
soluble fraction upon centrifugation of the 
sonicated cell suspension. The amount of this pro- 
tein, presumably 5LO, increased time-dependently 
after IPTG induction (not shown). Light 
microscopy indicated the presence of inclusion 
bodies in these cells, suggesting that 5LO syn- 
thesized under these conditions was encapsulated 
into the inclusion bodies. The insoluble fraction in- 
cluding the inclusion bodies was solubilized with 
6 M guanidine hydrochloride and then subjected 
to a protein renaturation procedure [19], however 
no 5LO activity could be detected. Nevertheless, 
when the copy number of the expression plasmid 
was decreased by growing transformed cells at 
20°C for 15 h after IPTG induction, the soluble 
fraction showed 5LO activity and upon SDS- 
PAGE displayed a protein band of 78 kDa (fig.2, 
lane 1). 
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Fig.2. SDS-PAGE of fractions obtained from the purification 
of 5LO. Samples were loaded onto an SDS-10% polyacryl- 
amide gel, electrophoresed and stained with Coomassie brilliant 
blue R250. Lanes: (1) 10000 x g supernatant, (2) 30-60% am- 
monium sulfate precipitate, (3) Q-Sepharose, (4) Blue 
Sepharose, (5) hydroxyapatite, (6)MonoQ HR 5/5. 
An attempt was therefore made to purify 5LO 
from the soluble fraction of the cells grown at 
20°C as described in section 2.3, with progress of 
purification being monitored by SDS-PAGE 
(fig.2, lanes 2-6). As can be seen, the 78 kDa pro- 
tein was finally purified to homogeneity by am- 
monium sulfate fractionation followed by 
chromatography on Q-Sepharose, Blue Sepharose, 
hydroxyapatite and Mono Q columns. 5LO activi- 
ty was thereby purified about 390-fold with an 
overall yield of 4.4°/0. About 160/zg purified 5LO 
was obtained from 1.8 I culture. The yield of 5LO 
from human peripheral blood leukocytes has been 
reported to be only 1.5% [7]. 
As shown in fig.3, the 5LO activity of the en- 
zyme purified from transformed E. coli cells 
showed similar requirements for Ca 2+ and ATP to 
those reported for human leukocyte 5LO activity 
[1,7]. Like the enzyme from human leukocytes 
[10], 5LO purified in this study was also activated 
by sonicated phosphatidylcholine (not shown). 
The purified enzyme also showed LTA4 synthase 
activity in the presence of both Ca 2+ and ATP (not 
shown). The synthesis of LTA4 was estimated from 
the sum of the areas of peaks of 6E,5(S),12(R)- 
LTB4 (retention time, 11.0 min) and 6E,5(S), 
12(S)-LTB4 (retention time, 11.7 min) divided by 
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leukocytes. This expression system thus makes it 
possible to produce human 5LO in sufficiently 
large quantities for detailed structural studies and 
development of ant i - inf lammatory chemo- 
therapeutic agents. 
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Fig.3. Effects of Ca 2+ and ATP concentration on 5LO ac- 
tivities. (A) 1/zg purified 5LO was assayed for the activity of 
conversion to 5-HPETE in the presence of2 mM ATP and the 
indicated concentration f Ca 2+. (B) Conditions as for A except 
that samples contained 2 mM Ca 2+ and the ATP concentration 
was varied as indicated. 
that of the PGBI peak (retention time, 9.2 min). 
Assuming that the two LTB4 isomers have a molar 
extinction coefficient of 51 000 at 270 nm [20], it 
was calculated that conversion of arachidonic acid 
to 5 -HPETE and of the latter to LTA4 amounted 
to 30 and 35°70, respectively. No proteinaceous 
st imulatory factors were required for both 5LO 
and LTA4 synthase activities. 
NH2-terminal sequence analysis howed that the 
first 29 amino acid residues of the enzyme purified 
here were in complete agreement with those of 
purif ied human leukocyte 5LO [11]. Since this se- 
quence started with proline, but not methionine, it 
was concluded that the processing of the initiator 
methionine residue had taken place in the E. coli 
system as in the leukocyte system. 
The observations described above indicate that 
the 5LO purified from transformed E. coli cells 
was identical with that obtained from human 
REFERENCES 
[1] Rouzer, C.A., Matsumoto, T. and Samuelsson, B. (1986) 
Proc. Natl. Acad. Sci. USA 83, 857-861. 
[2] Ueda, N., Kaneko, S., Yoshimoto, T. and Yamamoto, S. 
(1986) J. Biol. Chem. 261, 7982-7988. 
[3] Hogaboom, G.K., Cook, M., Newton, J.F., Varrichio, 
A., Short, R.G.L., Sarau, H.M. and Crooke, S.T. (1986) 
Mol. Pharmacol. 30, 510-519. 
[4] Shimizu, T., Izumi, T., Seyama, Y., Tadokoro, K., 
R~tdmark, O. and Samuelsson, B. (1986) Proc. Natl. 
Acad. Sci. USA 83, 4175-4179. 
[5] Samuelsson, B. (1983) Science 220, 568-575. 
[6] Samuelsson, B., Dahl~n, S.-E., Lindgren, J.A., Rouzer, 
C.A. and Serhan, C.N. (1987) Science 237, 1171-1176. 
[7] Rouzer, C.A. and Samuelsson, B. (1985) Proc. Natl. 
Acad. Sci. USA 82, 6040-6044. 
[8] Goetze, A.M., Fayer, L., Bouska, J., Bornemeier, D. and 
Carter, G.W. (1985) Prostaglandins 29, 689-701. 
[9] Rouzer, C.A., Shimizu, T. and Samuelsson, B. (1985) 
Proc. Natl. Acad. Sci. USA 82, 7505-7509. 
[10] Puustinen, T., Scheffer, M.M. and Samuelsson, B. (1988) 
Taipei Conference on Prostaglandin and Leukotriene Re- 
search, abstr., p. 159. 
[11] Matsumoto, T., Funk, C.D., Rhdmark, O., H66g, J.-O., 
J6rnvall, H. and Samuelsson, B. (1988) Proc. Natl. Acad. 
Sci. USA 85, 26-30 and correction p. 3406. 
[12] Dixon, R.A.F., Jones, R.E., Diehl, R.E., Bennett, C.D., 
Kargman, S. and Rouzer, C.A. (1988) Proc. Natl. Acad. 
Sci. USA 85, 416-420. 
[13] Balcarek, J.M., Theisen, T.W., Cook, M.N., Varrichio, 
A., Hwang, S.-M., Strohsacker, M.W. and Crooke, S.T. 
(1988) J. Biol. Chem. 263, 13937-13941. 
[14] Hanahan, D. (1983) J. Mol. Biol. 166, 557-580. 
[15] Hattori, M. and Sakaki, Y. (1986) Anal. Biochem. 152, 
232-238. 
[16] Laemmli, U.K. (1970) Nature 227, 680-685. 
[17] Bradford, M.M. (1976) Anal. Biochem. 72, 248-254. 
[18] Miki, T., Yasukochi, T., Nagatani, H., Furuno, M., 
Orita, T., Yamada, H., Imoto, T. and Horiuchi, T. (1987) 
Protein Eng. 1, 327-332. 
[19] Marston, F.A.O. (1987) DNA Cloning (Glover, D.M. ed.) 
vol. 3, pp. 59-88, IRL, Oxford. 
[20] Jubiz, W. (1983) Biochem. Biophys. Res. Commun. 110, 
842-850. 
270 
